| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Eosinophils have been considered end-stage effector cells involved in allergic inflammation through their release of cytotoxic granule proteins. Eosinophil cytolysis is an activated phenotype that has been previously observed in biological specimens from patients with disease, and deposition of free eosinophil granules is readily observed in the affected tissues or secretions from these patients. Using pathological specimen and blood-derived human eosinophils, we reported that activated eosinophils undergo a distinct programed pathway of rapid non-apoptotic cell death, extracellular trap cell death (ETosis). ETosis involves the cytolytic release of intact granules also in conjunction with filamentous chromatin structures (DNA traps). Further, we showed that ETosis-mediated DNA traps abundantly present in eosinophilic secretions from patients with eosinophilic chronic rhinosinusitis and contributed to increase their viscosity and chronic inflammation.
|
